Furiex Pharmaceuticals, Inc. Confirms Takeda Pharmaceutical Co. Ltd. Launches LIOVEL(R) LD and LIOVEL(R) HD, a Fixed Dose Combination of NESINA(R) and ACTOS(R), for Type 2 Diabetes in Japan
Published: Sep 21, 2011
MORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) today confirmed that Takeda Pharmaceutical Company Limited (“Takeda”) has launched two dosages of LIOVEL®, a fixed dose combination tablet of NESINA® (alogliptin) and ACTOS® (pioglitazone HCL), in Japan for the treatment of Type 2 diabetes.
Furiex developed NESINA, which is a member of the dipeptidyl peptidase IV (DPP-4) inhibitor class, in collaboration with Takeda’s wholly-owned subsidiary, Takeda San Diego, Inc. LIOVEL LD and LIOVEL HD contain 25 mg alogliptin/15 mg pioglitazone and 25 mg alogliptin/30 mg pioglitazone, respectively.
“We are very pleased with Takeda’s launch of LIOVEL in Japan, a new product using the drug NESINA,” said June Almenoff, M.D., Ph.D., president and chief medical officer of Furiex. “This launch adds to Furiex’s revenue stream and confirms our strategy of partnering drug candidates in return for royalty payments.”
Under Furiex’s agreement with Takeda, this launch does not trigger a milestone payment to Furiex. However, Furiex is entitled to receive royalty payments on sales of LIOVEL.
Furiex Pharmaceuticals is a drug development collaboration company using innovative clinical development design to accelerate and increase value of internal and partnered drug programs by advancing them through the drug discovery and development process in a cost-efficient manner. Development programs are designed and driven by a core team with extensive drug development experience. Furiex collaborates with pharmaceutical and biotechnology companies and has a strong, diversified product portfolio and pipeline with multiple therapeutic candidates including late-stage assets and two products on the market. Our mission is to develop innovative medicines faster and at a lower cost, thereby improving profitability and accelerating time to market while providing life-improving therapies for patients. For more information, visit www.furiex.com.
Except for historical information, all of the statements, expectations and assumptions contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although Furiex attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors which could cause actual results to differ materially include the following: failure of our partner to successfully market and sell its products; the demand for our partner’s products and the impact on future royalty payments; our potential need for additional financing; progress of product candidates in clinical trials as it relates to receiving future milestone and royalty payments; time required to gain regulatory approvals; and the other risk factors set forth from time to time in the SEC filings for Furiex, copies of which can be found on our website.
Furiex Pharmaceuticals, Inc.
Sailash Patel, 919-456-7814